

**Washington State Pharmacy and Therapeutics Committee &  
Drug Utilization Review Board**

**Date: December 20, 2017**

**Time: 9 a.m. to 2 p.m.**

**Port of Seattle “International A” Conference Room  
Seattle-Tacoma International Airport  
17801 International Blvd., Seattle, WA 98158**

9 a.m.	Welcome & Introductions <b>Pharmacy &amp; Therapeutics Committee Convenes</b>	Michael Johnson, Committee Chair
9 a.m.	Committee votes on new Chair and Vice Chair	Committee
9:05 a.m.	Atopic Dermatitis full review Immunomodulators, Atopic Dermatitis <ul style="list-style-type: none"> <li>• Stakeholder comment</li> <li>• Motion</li> </ul>	Marian McDonagh, OHSU Stephanie Christofferson, Magellan
9:55 a.m.	Asthma-COPD* scan	Marian McDonagh, OHSU
10:10 a.m.	Long-acting Insulins* full review	Marian McDonagh, OHSU
10:30 a.m.	Opioids * scan	Marian McDonagh, OHSU
10:45 a.m.	<b>Pharmacy &amp; Therapeutics Committee Adjourns</b>	Michael Johnson, Committee Chair
10:45 a.m.	<b>Break</b>	All
11 a.m.	<b>Drug Utilization Review (DUR) Board Convenes</b>	Michael Johnson, Committee Chair
11 a.m.	Review of clinical polices: <ul style="list-style-type: none"> <li>• Angiotensin modulators</li> <li>• Angiotensin modulator combinations</li> <li>• Beta-blockers</li> <li>• Calcium Channel Blockers <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• Anticoagulants</li> <li>• Antivertigo agents <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• Hypoglycemics, Alpha-Glucosidase Inhibitors</li> <li>• Hypoglycemics, Meglitinides</li> <li>• Hypoglycemics, Sulfonylureas</li> <li>• Hypoglycemics, TZD <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• GI Motility, chronic</li> <li>• Ulcerative Colitis agents <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• Motion</li> </ul>	Stephanie Christofferson, Magellan
12 p.m.	<b>Lunch</b>	All

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.

1 p.m.	<p>Review of clinical polices:</p> <ul style="list-style-type: none"> <li>• Antiparasitics, topical</li> <li>• Antibiotics, topical</li> <li>• Antibiotics, vaginal</li> <li>• Antibiotics, GI <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• Acne agents, topical</li> <li>• Antipsoriatic, oral</li> <li>• Antipsoriatic, topical <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• Skeletal muscle relaxants <ul style="list-style-type: none"> <li>○ Stakeholder comment</li> </ul> </li> <li>• Motion</li> </ul>	Stephanie Christofferson, Magellan
2 p.m.	<b>Drug Utilization Review Board Adjourns</b>	Michael Johnson, Committee Chair

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.